Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
for Nodular Lymphocyte Predominant B-Cell Lymphoma
Drug: Mosunetuzumab
35 locations incl. Duarte
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05886036·Phase 2·Recruiting